flecainide has been researched along with Batten Turner Congenital Myopathy in 6 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "More recently, severe neonatal episodic laryngospasm (SNEL) has been described in a small number of patients." | 2.53 | Flecainide-Responsive Myotonia Permanens With SNEL Onset: A New Case and Literature Review. ( Musumeci, O; Portaro, S; Rodolico, C; Sinicropi, S; Toscano, A; Valenzise, M, 2016) |
| "Residue G1306 Neonatal laryngospasm and unusual distribution of myotonia, muscle hypertrophy, and weakness encourage direct search for the G1306E mutation, a hotspot for de-novo mutations." | 1.46 | Myotonia permanens with Nav1.4-G1306E displays varied phenotypes during course of life. ( Bertini, E; D'Amico, A; Jurkat-Rott, K; Lehmann-Horn, F; Lomonaco, M; Merlini, L; Nelson, KR; Philippi, H; Siciliano, G; Spaans, F, 2017) |
| "An unusual form of painful congenital myotonia is associated with a novel SCN4A mutation causing a valine to methionine substitution in the domain 1/S6 segment of the skeletal muscle sodium channel." | 1.30 | Functional consequences of a domain 1/S6 segment sodium channel mutation associated with painful congenital myotonia. ( Bennett, PB; George, AL; Ruben, PC; VanDeCarr, D; Wang, DW, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lehmann-Horn, F | 1 |
| D'Amico, A | 2 |
| Bertini, E | 1 |
| Lomonaco, M | 2 |
| Merlini, L | 1 |
| Nelson, KR | 1 |
| Philippi, H | 1 |
| Siciliano, G | 1 |
| Spaans, F | 1 |
| Jurkat-Rott, K | 1 |
| Desaphy, JF | 3 |
| Carbonara, R | 2 |
| Costanza, T | 1 |
| Conte Camerino, D | 2 |
| Portaro, S | 1 |
| Rodolico, C | 1 |
| Sinicropi, S | 1 |
| Musumeci, O | 1 |
| Valenzise, M | 1 |
| Toscano, A | 1 |
| Modoni, A | 2 |
| Roussel, J | 1 |
| Imbrici, P | 1 |
| Pagliarani, S | 1 |
| Lucchiari, S | 1 |
| Lo Monaco, M | 1 |
| Camerino, DC | 1 |
| Wang, DW | 1 |
| VanDeCarr, D | 1 |
| Ruben, PC | 1 |
| George, AL | 1 |
| Bennett, PB | 1 |
1 review available for flecainide and Batten Turner Congenital Myopathy
| Article | Year |
|---|---|
Flecainide-Responsive Myotonia Permanens With SNEL Onset: A New Case and Literature Review.
Topics: Child; Female; Flecainide; Humans; Hypertrophy; Laryngismus; Muscle, Skeletal; Mutation; Myotonia Co | 2016 |
5 other studies available for flecainide and Batten Turner Congenital Myopathy
| Article | Year |
|---|---|
Myotonia permanens with Nav1.4-G1306E displays varied phenotypes during course of life.
Topics: Action Potentials; Adolescent; Adult; Age Factors; Child; Child, Preschool; Dyspnea; Exercise; Femal | 2017 |
Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
Topics: Animals; Carbamazepine; Disease Models, Animal; Flecainide; HEK293 Cells; Humans; Mexiletine; Muscle | 2014 |
Translational approach to address therapy in myotonia permanens due to a new SCN4A mutation.
Topics: Cell Line; Child; Diagnosis, Differential; Female; Flecainide; Humans; Mexiletine; Mutation; Myotoni | 2016 |
Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy.
Topics: Female; Flecainide; Humans; Male; Mutation; Myotonia Congenita; NAV1.4 Voltage-Gated Sodium Channel; | 2013 |
Functional consequences of a domain 1/S6 segment sodium channel mutation associated with painful congenital myotonia.
Topics: Animals; Anti-Arrhythmia Agents; Cell Line; Computer Simulation; Flecainide; Ion Channel Gating; Mem | 1999 |